Description
What this story covers
STERIS plc's Q2 fiscal 2026 10-Q shows 9.9% revenue growth to $1.46B, driven by services and consumables in Healthcare, AST, and Life Sciences segments. Operating income up 21.1%, cash flow at $708M, with debt reduction and strategic focus post-Dental divestiture. Backlog signals demand; risks managed via hedges.
Story snapshot
CompanySTERIS plc
TickerSTE
VariantStandard detailed
Duration10:31
Filing type10-Q
PeriodQ2 2026
IndustryHealthcare & Pharmaceuticals
Accession0001628280-25-050160
Full Story Script
Content not available for this story.
